News headlines about MISONIX (NASDAQ:MSON) have trended somewhat positive on Monday, according to Accern Sentiment Analysis. The research group ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. MISONIX earned a news sentiment score of 0.09 on Accern’s scale. Accern also assigned headlines about the medical equipment provider an impact score of 47.1705456667543 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

ILLEGAL ACTIVITY NOTICE: This story was first published by Daily Political and is owned by of Daily Political. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.dailypolitical.com/2017/09/25/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-misonix-mson-share-price.html.

About MISONIX

Misonix, Inc designs, manufactures, develops and markets minimally invasive therapeutic ultrasonic medical devices. The Company’s products include BoneScalpel surgical system (BoneScalpel), SonaStar Surgical Aspirator (SonaStar), and SonicOne Wound Cleansing and Debridement System (SonicOne). These devices primarily serve the neurosurgery, orthopedic surgery, plastic surgery, wounds, burn and maxillo-facial clinical specialties.

Insider Buying and Selling by Quarter for MISONIX (NASDAQ:MSON)

Receive News & Ratings for MISONIX Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MISONIX Inc. and related companies with MarketBeat.com's FREE daily email newsletter.